A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
Status: Recruiting
Location: See all (44) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 130
Healthy Volunteers: f
View:
• Patient willing and able to provide written informed consent to participate in the study
• Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
• Aged ≥18 years at the time of signing the informed consent
• Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)